La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Exscientia Gestion

Gestion contrôle des critères 1/4

Le PDG Exscientia's est Dave Hallett, nommé en Feb2023, a un mandat de 1.5 ans. détient directement 0.001% des actions de la société, d'une valeur de € 7.43K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.5 ans et 3.6 ans.

Informations clés

Dave Hallett

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	1.7yrs
Propriété du PDG	0.001%
Durée moyenne d'occupation des postes de direction	1.7yrs
Durée moyenne du mandat des membres du conseil d'administration	3.8yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Dave Hallett (55 yo)

1.7yrs

Titularisation

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
David Hallett	Chief Scientific Officer	1.7yrs	pas de données	0.0012% € 7.2k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.9yrs	UK£1.92m	0.062% € 383.9k
John Overington	Chief Technology Officer	less than a year	pas de données	0.015% € 94.0k
Sara Sherman	Vice President of Investor Relations	no data	pas de données	pas de données
Dan Ireland	Executive VP of Legal & Company Secretary	1.8yrs	pas de données	pas de données
Parker Moss	Executive Vice President of Corporate Development	less than a year	pas de données	pas de données
Caroline Rowland	Chief People Officer	2.1yrs	pas de données	pas de données
Richard Law	Chief Business Officer	no data	pas de données	pas de données
Nikolaus Krall	Executive Vice President of Precision Medicine	1.8yrs	pas de données	pas de données
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	pas de données	pas de données

1.7yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0RK n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
David Hallett	Chief Scientific Officer	less than a year	pas de données	0.0012% € 7.2k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.9yrs	UK£1.92m	0.062% € 383.9k
Elizabeth Crain	Independent Non-Executive Chairman	3.7yrs	UK£282.03k	0.089% € 552.4k
Mario Polywka	Independent Non-Executive Director	7.1yrs	UK£201.69k	0.053% € 327.3k
Robert Ghenchev	Independent Non-Executive Director	4.4yrs	pas de données	pas de données
Franziska Michor	Independent Director	1.4yrs	UK£178.86k	0.028% € 174.1k

3.8yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0RK sont considérés comme expérimentés (ancienneté moyenne 3.6 ans).

Exscientia Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023)

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Third quarter 2022 earnings released: UK£0.29 loss per share (vs UK£59.17 loss in 3Q 2021)

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Less than half of directors are independent

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

High number of new directors

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen